Back to top

Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

Jefferies analyst Akash Tewari maintained a Buy rating on Spyre Therapeutics today and set a price target of $98.00. Tewari covers the Healthcare s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Spyre Therapeutics, Inc. (SYRE)